FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119198740> ?p ?o ?g. }

• W2119198740 endingPage "5598" @default.
• W2119198740 startingPage "5591" @default.
• W2119198740 abstract "Abstract Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylactic budesonide (Entocort EC), a nonabsorbed oral steroid, reduced the rate of grade ≥2 diarrhea in ipilimumab-treated patients with advanced melanoma. Experimental Design: Previously treated and treatment-naïve patients (N = 115) with unresectable stage III or IV melanoma received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) with daily blinded budesonide (group A) or placebo (group B) through week 16. The first scheduled tumor evaluation was at week 12; eligible patients received maintenance treatment starting at week 24. Diarrhea was assessed using Common Terminology Criteria for Adverse Events (CTCAE) 3.0. Patients kept a diary describing their bowel habits. Results: Budesonide did not affect the rate of grade ≥2 diarrhea, which occurred in 32.7% and 35.0% of patients in groups A and B, respectively. There were no bowel perforations or treatment-related deaths. Best overall response rates were 12.1% in group A and 15.8% in group B, with a median overall survival of 17.7 and 19.3 months, respectively. Within each group, the disease control rate was higher in patients with grade 3 to 4 irAEs than in patients with grade 0 to 2 irAEs, although many patients with grade 1 to 2 irAEs experienced clinical benefit. Novel patterns of response to ipilimumab were observed. Conclusions: Ipilimumab shows activity in advanced melanoma, with encouraging survival and manageable adverse events. Budesonide should not be used prophylactically for grade ≥2 diarrhea associated with ipilimumab therapy. (Clin Cancer Res 2009;15(17):5591–8)" @default.
• W2119198740 created "2016-06-24" @default.
• W2119198740 creator A5000421781 @default.
• W2119198740 creator A5000470144 @default.
• W2119198740 creator A5028479135 @default.
• W2119198740 creator A5028592995 @default.
• W2119198740 creator A5033513252 @default.
• W2119198740 creator A5044347261 @default.
• W2119198740 creator A5047177507 @default.
• W2119198740 creator A5060495866 @default.
• W2119198740 creator A5060816944 @default.
• W2119198740 creator A5064130672 @default.
• W2119198740 creator A5078577056 @default.
• W2119198740 creator A5088232810 @default.
• W2119198740 date "2009-08-31" @default.
• W2119198740 modified "2023-10-03" @default.
• W2119198740 title "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma" @default.
• W2119198740 cites W1762668067 @default.
• W2119198740 cites W1818891252 @default.
• W2119198740 cites W1845726423 @default.
• W2119198740 cites W1879616740 @default.
• W2119198740 cites W1917632054 @default.
• W2119198740 cites W1950572133 @default.
• W2119198740 cites W1982889687 @default.
• W2119198740 cites W1987419250 @default.
• W2119198740 cites W2011852843 @default.
• W2119198740 cites W2020727013 @default.
• W2119198740 cites W2021988012 @default.
• W2119198740 cites W2041672829 @default.
• W2119198740 cites W2056336637 @default.
• W2119198740 cites W2064069118 @default.
• W2119198740 cites W2094366129 @default.
• W2119198740 cites W2107150019 @default.
• W2119198740 cites W2109465910 @default.
• W2119198740 cites W2109513968 @default.
• W2119198740 cites W2134638467 @default.
• W2119198740 cites W2137591261 @default.
• W2119198740 cites W2137723371 @default.
• W2119198740 cites W2145308813 @default.
• W2119198740 cites W2145853100 @default.
• W2119198740 cites W2146887062 @default.
• W2119198740 cites W2151507811 @default.
• W2119198740 cites W2152194859 @default.
• W2119198740 cites W2161550811 @default.
• W2119198740 cites W2203317209 @default.
• W2119198740 cites W2246726729 @default.
• W2119198740 cites W2254875398 @default.
• W2119198740 cites W2260073192 @default.
• W2119198740 cites W2275603381 @default.
• W2119198740 cites W2330814896 @default.
• W2119198740 cites W2341290590 @default.
• W2119198740 cites W2528032056 @default.
• W2119198740 cites W2589187209 @default.
• W2119198740 cites W2589804830 @default.
• W2119198740 cites W2265899709 @default.
• W2119198740 doi "https://doi.org/10.1158/1078-0432.ccr-09-1024" @default.
• W2119198740 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19671877" @default.
• W2119198740 hasPublicationYear "2009" @default.
• W2119198740 type Work @default.
• W2119198740 sameAs 2119198740 @default.
• W2119198740 citedByCount "503" @default.
• W2119198740 countsByYear W21191987402012 @default.
• W2119198740 countsByYear W21191987402013 @default.
• W2119198740 countsByYear W21191987402014 @default.
• W2119198740 countsByYear W21191987402015 @default.
• W2119198740 countsByYear W21191987402016 @default.
• W2119198740 countsByYear W21191987402017 @default.
• W2119198740 countsByYear W21191987402018 @default.
• W2119198740 countsByYear W21191987402019 @default.
• W2119198740 countsByYear W21191987402020 @default.
• W2119198740 countsByYear W21191987402021 @default.
• W2119198740 countsByYear W21191987402022 @default.
• W2119198740 countsByYear W21191987402023 @default.
• W2119198740 crossrefType "journal-article" @default.
• W2119198740 hasAuthorship W2119198740A5000421781 @default.
• W2119198740 hasAuthorship W2119198740A5000470144 @default.
• W2119198740 hasAuthorship W2119198740A5028479135 @default.
• W2119198740 hasAuthorship W2119198740A5028592995 @default.
• W2119198740 hasAuthorship W2119198740A5033513252 @default.
• W2119198740 hasAuthorship W2119198740A5044347261 @default.
• W2119198740 hasAuthorship W2119198740A5047177507 @default.
• W2119198740 hasAuthorship W2119198740A5060495866 @default.
• W2119198740 hasAuthorship W2119198740A5060816944 @default.
• W2119198740 hasAuthorship W2119198740A5064130672 @default.
• W2119198740 hasAuthorship W2119198740A5078577056 @default.
• W2119198740 hasAuthorship W2119198740A5088232810 @default.
• W2119198740 hasBestOaLocation W21191987402 @default.
• W2119198740 hasConcept C121608353 @default.
• W2119198740 hasConcept C126322002 @default.
• W2119198740 hasConcept C141071460 @default.
• W2119198740 hasConcept C142724271 @default.
• W2119198740 hasConcept C168563851 @default.
• W2119198740 hasConcept C197934379 @default.
• W2119198740 hasConcept C204787440 @default.
• W2119198740 hasConcept C27081682 @default.
• W2119198740 hasConcept C2776136866 @default.
• W2119198740 hasConcept C2776804153 @default.
• W2119198740 hasConcept C2777701055 @default.

• next